Engimmune Therapeutics’ Post

𝐈𝐧𝐒𝐢𝐥𝐢𝐜𝐨𝐓𝐫𝐢𝐚𝐥𝐬 𝐚𝐭 𝐁𝐈𝐎 𝟐𝟎𝟐𝟒: 𝐀𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐆𝐥𝐨𝐛𝐚𝐥 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 🗓 June 3-6 | San Diego Convention Center   InSilicoTrials is excited to announce our participation in the 2024 BIO International Convention, the premier global event for #biotechnology. You can find us at #Booth3623 in the bustling exhibition hall.   🇮🇹 Proudly representing the cutting-edge of #Italianinnovation in healthcare technology, we are part of the ITA - Italian Trade Agency delegation. This year, the Italian Pavilion will feature 20 leading #biotech companies, #startups, and clusters active across various sectors of the #lifesciences space, including #pharmaceuticals #medicaldevices #digitalhealth, and biotechnology.   Our leadership team, including CEO Luca Emili and Chief Operating Officer Mario Torchia, will be available to discuss how our platform is integrating #AI and #insilico technology to speed up #drugdevelopment and support biotech companies by generating robust #digitalevidence to enhance funding prospects and #clinicaloutcomes.   🙌 Join us at our booth, engage with our team, and learn more about our impactful work in the #biotechindustry. We look forward to connecting with U.S. partners and investors, establishing new business relationships, and continuing to push the boundaries of #healthcare innovation. ℹ https://lnkd.in/dAukxhq

Just leaving from Lille from NutrEvent, but exciting times ahead at #CPHIMilan2024! 🌍  From October 8-10, the global pharma community will gather in Milan for the largest gathering of industry leaders, innovators, and partners. With over 62,000 attendees and 2,400+ exhibitors, this event is a prime opportunity to connect and explore advancements across the pharma supply chain. AXXSense will be part of this important event - as a scientific platform specializing in the discovery of novel taste and olfactory modulators, we are at the forefront of innovative solutions that span various sectors, including pharmaceuticals, food, and cosmetics. Our expertise in high-throughput screening and compound profiling will contribute to vital discussions on the future of drug discovery and sensory science. If you're attending, don't miss the chance to connect and engage with thought leaders on topics such as AI in bio-manufacturing, sustainable practices, and patient-centric therapies. Let’s drive innovation and enhance patient access together! 💊💡 Looking forward to seeing everyone in Milan! #CPHIMilan2024 #ScientificPlatform #SensoryScience #FoodIndustry #FragranceIndustry #CosmeticsIndustry #PetFoodIndustry

How can cell therapy be made more efficient, cheaper and accessible? The trend towards Allogeneic treatment versus autologous is essential. Daring moves towards using multiple types of cells may open new horizons for a better cell therapy, a multicell therapy. Understanding the natural, physiological mechanisms of immunity and regeneration can help us too. Prevention based on rejuvenation using for example stem cells, lowering inflammation, may help avoiding cancer in the first place (Panel discussion themes and conclusions).

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #13.   We are talented: We were founded by bright minds. We have attracted highly talented employees and we support them to expand their skills and achievements. Our chairman is world-renowned in the field of rare diseases. Our leadership team is highly experienced and highly regarded. We value camaraderie and interdependencies between us as a team, and with the environment in which we operate.   Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf   #innovation #biotech #drugdiscovery

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #3. We are ambitious: We are driven by our shared mission to discover, develop and deliver impactful medicines to patients using cutting edge science. We are motivated to push boundaries and think big as we tackle challenges we confront as a company. We take a proactive approach towards research, and we are intentional in setting our short-term and long-term goals. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery

🚀 Exciting news! We’re heading to BioTechX Europe this October.   Get ready for two days packed with innovation, as we connect with industry leaders, dive deep into the latest breakthroughs in AI-driven drug discovery, and explore transformative collaborations.   🗓️ When: October 9-10, 2024 📍 Where: Messe Basel, Switzerland   This is a golden opportunity to network with inspiring minds, learn cutting-edge trends, and gain insights that will shape the future of pharma and biotech. 💡   We can’t wait to bring back new ideas and partnerships that will fuel the next wave of innovation in pharma.   At Entvin, we’re transforming unstructured documents to fuel LLMs and drive innovation in Life Sciences.   🤝 Also, don't miss out on discussing how Entvin can unlock new potential for your pharma research, streamline innovation, and accelerate breakthroughs.   Meeting Link: https://lnkd.in/gWVWfpsN   See you at BioTechX Europe!   #BioTechX #AIInPharma #BioTechXEurope #Innovation #Networking #Pharma #AI

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #5. We are responsible: We take personal and collective responsibility for delivering our shared goals. We hold ourselves and each other accountable – to our patients, colleagues, investors, as well as our work and mission. We apply the necessary rigor to ensure high quality. We are self-motivated and rely on each other to operate and perform at the highest levels. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery

Proud to be part of it! #Fightantimicrobialresistance BIOASTER INCATE #antibiotics INCATE marks its third anniversary of successfully supporting innovators fighting antimicrobial resistance https://lnkd.in/eEpXjP9F About INCATE INCATE is a not-for-profit partnership which brings together translational and basic research, industry, experienced entrepreneurs, and investors from across Europe and beyond. The German Center for Infection Research (DZIF), the Leibniz:HKI (part of Leibniz Association) in Germany, the Swiss National Centre of Competence in Research AntiResist, the University of Basel, are the academic founding members of INCATE, with the University of Basel acting as the host. Together with the four industry partners Boehringer Ingelheim, MSD, Roche, and Shionogi, the Technology transfer organization BIOASTER in France, and US-based venture capital firm Kineticos AMR Accelerator Fund, as well as other organizations, funders and investors, INCATE aims to ensure that the pipeline of new antibiotics and technology platforms is filled and strengthened.

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #6. We are focused: To ensure alignment with our mission, we take a focused approach to our delivery. We wisely utilise our resources and pay attention to our priorities. We balance pursuing our ambitious goals and innovations with our ability to ”focus and finish”. We focus on our most important work, and we are clear on our daily priorities to deliver our collective goals and mission. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery

I attended Pernilla Isberg’s keynote talk Lab of the Future, where she discussed many exciting aspects of supporting innovation in the lab. AstraZeneca BioVentureHub was established in 2015 as a unique innovation platform in the heart of AstraZeneca’s R&D site in Gothenburg, focusing on scaling up and offering industry support with no strings attached to emerging companies within Life Science. With big ambitions, they are honing in on joint value creation, which includes: 👉 Joint Scientific Collaborations – Involving 41 joint publications with AstraZeneca 👉 People Development – Access to AstraZeneca scientific expertise 👉 Sustainability – Allow SME companies to have direct benefits of the AstraZeneca sites sustainability initiatives and a tailored ‘My Green Lab’ certification program for all lab-based BVH companies 👉 BHV Company growth (2023) – There were 48 new employees, 6 new products and 33 new patents. BVH welcome new companies to join the hub, with a focus on areas where they can solve challenges and opportunities together with AstraZeneca. These include; 📌 Pharma: New modalities and drug delivery technologies 📌 Data/AI: For safer and faster development of drugs 📌Deep tech: Enabling R&D technologies 📌Sustaintech: CO2 utilisation, biocatalysis, green chemistry and waste valorisation The biggest takeaway from this talk was inspiring us all to turn an ‘EGOsystem’ into an ‘Ecosystem’! #LOTFEU2024 #BiotechInnovation #ThoughtLeadership #Technology